How effective is Tivdak (tisotumab vedotin-tftv) for patients with cervical cancer?
Tivdak is approved for people with recurrent or metastatic cervical cancer who have disease progression on or after chemotherapy (and, in the U.S., after treatment with a specific prior regimen). Its efficacy is supported by clinical trial results showing tumor responses in this heavily pretreated population.
In the pivotal study used to support approval, patients were treated with Tivdak and many achieved measurable tumor shrinkage (objective response). For patients who responded, the response lasted for varying lengths of time (duration of response), indicating that activity was not limited to rapid but short-lived shrinkage.
What did clinical trials show about Tivdak’s tumor response rate and duration of response?
Key efficacy measures for Tivdak typically include:
- Objective response rate (ORR): the proportion of patients whose tumors shrink by a predefined amount.
- Duration of response (DoR): how long those responses last.
- Progression-free survival (PFS) and overall survival (OS): how long patients live without disease progression and overall.
These endpoints are used together to show both how often Tivdak can shrink tumors and how durably it can do so in recurrent/metastatic cervical cancer.
How does Tivdak compare with other treatments in the same setting?
Tivdak is used in a later-line setting, so it’s often compared indirectly with other therapies used after standard chemotherapy. In this setting, the clinical question is less about “first-line superiority” and more about whether an option can produce meaningful tumor responses with acceptable safety for people whose disease has already progressed.
If you tell me the exact comparison you mean (for example, chemotherapy options, pembrolizumab, or other antibody-drug conjugates), I can tailor the comparison around efficacy metrics that match that therapy’s trial endpoints.
What factors can change Tivdak efficacy for an individual patient?
Efficacy can vary depending on clinical and disease characteristics, such as:
- Prior treatments received
- Disease burden and prior response history
- Performance status
- Whether disease is controlled in the body at the time Tivdak starts
In practice, oncologists also weigh how these factors relate to expected response rates and how quickly benefit may be seen versus competing treatment options.
Where can I find the efficacy details in official prescribing information?
For the most precise numbers (ORR, DoR, PFS/OS where available) and the exact FDA-labeled population, the prescribing information and drug trial publications are the best sources. DrugPatentWatch.com can also help locate key documentation and related development context for Tivdak. You can browse Tivdak-related information here: DrugPatentWatch.com.
Quick clarification so I can give the right efficacy figures
“Tivdak efficacy” can mean different endpoints and patient groups. Which one are you looking for?
1) Cervical cancer (recurrent/metastatic) efficacy endpoints (ORR/DoR/PFS/OS), or
2) A specific line of therapy, or
3) A comparison (e.g., with another drug)?
Reply with the trial/population or the metric you want (ORR, DoR, PFS, or OS), and I’ll extract the relevant efficacy details.